SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Micrologix biotech
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: checkmate who wrote (483)4/27/1999 6:16:00 PM
From: Robert Ling  Read Replies (1) of 792
 
good news....

Micrologix successfully completes Phase I clinical trial for the prevention of bloodstream infections

VANCOUVER, April 27 /CNW/ - Micrologix Biotech Inc.
Trading Symbol:
MBI (TSE/VSE)
MGIXF (US over the counter)

Micrologix Biotech Inc. is pleased to announce that it has successfully
completed a two-part Phase I human clinical trial of MBI 226, its lead Bactolysin drug candidate for preventing bloodstream infections in patients undergoing central venous catheterization. The study showed that MBI 226 is safe and well tolerated, eliminates 99.9% of bacteria commonly found on the skin and prevents bacterial growth on catheters. We will present these results to the United States FDA and intend to initiate Phase II clinical trials in the second half of this year.
The Centers for Disease Control and Prevention in Atlanta estimate that
in the US alone, 200,000 hospital patients contract bloodstream infections each year. Central venous catheters (CVCs) cause more than 90% of these infections, and on average, infected patients spend an additional 6.5 days in intensive care at a cost of $29,000. The associated mortality rate is high: up to 50,000 patients die annually from these bloodstream infections. As a result of the serious morbidity and mortality rates associated with these infections, the FDA announced in September 1998 that it is placing a high priority on supporting the development and approval of drugs to prevent and treat bloodstream infections. More effective means of prevention or treatment would save many lives and billions of dollars in health care costs in North America alone.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News